Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.

Machine translation Machine translation
作者
类别 Primary study
期刊Australian and New Zealand journal of medicine
Year 1991
Loading references information
20例中重度帕金森氏症患者的疗效进入了一个缓慢的释放和左旋多巴制剂含有200毫克的安全开放的研究和卡比多巴每片50毫克('心宁美达极')。经初步四周基线常规'心宁美粒稳定期,病人被转移到'心宁美达极'和观察的时间间隔,在未来12个月。 15例患者完成了全年的观察期。与基线相比时期,'心宁美达极'与功能的改善,减少波动的反应时间较长有关下列各剂量治疗。中位数(范围)剂量频率减少到3(3 - 12)2(2 - 7)每日三次(P比0.001较少)对'心宁美达极'尽管中位数(范围)的总左旋多巴每日剂量从700增加(375-2525)到800(400-2800)毫克没有任何不良影响的增加。 3例患者周围神经病变而接受心宁美达极,但与此疗法协会目前还不清楚。全部'心宁美达极'允许剂量间隔较长,以及提供更稳定的疾病表现比对照常规'心宁美'。
Epistemonikos ID: 22a8375c4e0fcfdb1985baec0d15118888f4b3c1
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use